Business Context and Reporting Period
Company: Anavex Life Sciences Corp.
Filing Type: Form 10-K (Annual Report)
Period Ended: September 30, 2010
Business Overview: Anavex is a biopharmaceutical company in the development stage, focused on discovering and developing novel drug targets for neurodegenerative diseases (Alzheimer's, epilepsy, depression) and cancer using its proprietary SIGMACEPTOR platform. The company has no commercial revenue and relies on equity and debt financing to fund research and development (R&D).
Key Financial Metrics
| Metric | Fiscal Year 2010 | Fiscal Year 2009 |
|---|---|---|
| Revenue | $0 | $0 |
| Total Expenses | $5,648,268 | $4,739,602 |
| Net Loss | $(8,783,037) | $(5,499,419) |
| Accumulated Deficit (Inception to 9/30/10) | $(21,896,074) | $(12,562,233) |
| Cash and Cash Equivalents (End of Period) | $264,669 | $350,994 |
| Working Capital Deficit | $(2,964,313) | $(3,691,514) |
| Current Liabilities | $3,290,071 | $4,098,466 |
| Loss Per Share (Basic & Diluted) | $(0.41) | $(0.27) |
Material Changes vs. Prior Period
- Expense Increase: Total operating expenses increased by approximately $909,000 (19%) year-over-year.
- R&D Expenses: Increased by $589,042 to $2.73 million, driven by preclinical and clinical preparation for the lead candidate ANAVEX 2-73.
- Legal Fees: Increased by $78,578 due to private placement activities and clinical trial agreements.
- Travel Expenses: Increased by $107,432 related to fundraising and clinical trial activities.
- Non-Operating Losses: The 2010 net loss was significantly impacted by non-cash items, including a $1.84 million accretion of debt discount, a $630,774 change in fair value of derivative liabilities, and a $444,000 loss on the settlement of accounts payable via equity issuance.
- Financing Activity: The company raised $3.1 million from the issuance of common shares and $1.4 million from promissory notes during the fiscal year.
Guidance, Outlook, and Risks
- Going Concern: The company's independent auditors have issued a "going concern" opinion, citing substantial doubt about the company's ability to continue operations due to recurring losses and an accumulated deficit. Management states the company requires approximately $10 million for the 12 months ending September 30, 2011, primarily to fund clinical trials for ANAVEX 2-73.
- Outlook: The lead drug candidate, ANAVEX 2-73 (targeting Alzheimer's disease), is expected to enter first Human Clinical Trials (HCT) in the first quarter of 2011. Preclinical work on other CNS compounds (epilepsy, depression) is planned for 2011 contingent on capital availability.
- Risks:
- Capital Shortfall: Failure to secure additional financing could force the company to delay, reduce, or cease R&D activities.
- Regulatory & Clinical Risk: No assurance that compounds will receive regulatory approval or succeed in clinical trials.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, including insufficient segregation of duties and lack of technical accounting knowledge.
Investor Verification Checklist
- Cash Runway: Verify if the company has secured the estimated $10 million required for the upcoming fiscal year to fund clinical trials.
- Debt Obligations: Review the terms of outstanding promissory notes, including interest rates and conversion features, which contributed significantly to the net loss via accretion.
- Internal Controls: Assess the progress of remediation plans for the identified material weaknesses in financial reporting controls.
- Clinical Milestones: Monitor the actual start date of Phase I clinical trials for ANAVEX 2-73, currently projected for Q1 2011.
- Dilution Risk: Evaluate the impact of recent and potential future equity issuances used to settle debt and fund operations on existing shareholder value.